CEFMINOX

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H21N7O7S3
Molecular Weight	519.576
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)CSC[C@@H](N)C(O)=O)OC)C(O)=O

InChI

InChIKey=JSDXOWVAHXDYCU-VXSYNFHWSA-N

InChI=1S/C16H21N7O7S3/c1-22-15(19-20-21-22)33-4-7-3-32-14-16(30-2,13(29)23(14)10(7)12(27)28)18-9(24)6-31-5-8(17)11(25)26/h8,14H,3-6,17H2,1-2H3,(H,18,24)(H,25,26)(H,27,28)/t8-,14-,16+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C16H21N7O7S3
Molecular Weight	519.576
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://cefminox-sodium.blogspot.ru/2012/05/cefminox-sodium-apollo-9191-46-950-950.html
Curator's Comment: Description was created based on several sources, including http://www.toku-e.com/Cefminox-sodium-P646.aspx and http://www.ncbi.nlm.nih.gov/pubmed/9517922

Cefminox is a broad-spectrum, bactericidal cephalosporin antibiotic. It is especially effective against Gram-negative and anaerobic bacteria. It is indicated in treatment of the following infections caused by sensitive bacteria: 1. Respiratory infections: Amygdalitis, circumtonsillar abscess, bronchitis, bronchiolitis, bronchiectasis (in fection), secondary infections of chronic respiratory diseases, pneumonia, and pulmonary suppuration; 2. Infection in urinary system: Nephropyelitis, cystitis; 3. Infections in abdominal cavity: Cholecystitis' angiocholitis'peritonitis; 4. Infections in pelvic cavity: Pelvic peritonitis, adnexitis, intrauterine infection, inflammation in pelvic dead space, and parametritis; 5. Septicaemia.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Escherichia coli growth 23 Target ID: Escherichia coli growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/25672407	Inhibitor 8297
Peptidoglycan biosynthesis 20 Target ID: map00550 Sources: http://www.genome.jp/dbget-bin/www_bget?D01909+D07642	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Bronchitis 51 Sources: http://cefminox-sodium.blogspot.ru/2012/05/cefminox-sodium-apollo-9191-46-950-950.html	Curative	Preclinical	Unknown Approved Use Unknown
Pneumonia 90 Sources: http://cefminox-sodium.blogspot.ru/2012/05/cefminox-sodium-apollo-9191-46-950-950.html	Curative	Preclinical	Unknown Approved Use Unknown
Cystitis 27 Sources: http://cefminox-sodium.blogspot.ru/2012/05/cefminox-sodium-apollo-9191-46-950-950.html	Curative	Preclinical	Unknown Approved Use Unknown
Septicaemia 15 Sources: http://cefminox-sodium.blogspot.ru/2012/05/cefminox-sodium-apollo-9191-46-950-950.html	Curative	Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Cefminox: correlation between in-vitro susceptibility and pharmacokinetics and serum bactericidal activity in healthy volunteers.	1994 Jan	8157579
In vitro activities of cefminox against anaerobic bacteria compared with those of nine other compounds.	1998 Mar	9517922
Synthesis of cefminox by cell-free extracts of Streptomyces clavuligerus.	2000 Jan 15	10620685
Determination of MIC distribution of arbekacin, cefminox, fosfomycin, biapenem and other antibiotics against gram-negative clinical isolates in South India: a prospective study.	2014	25068396
In Vitro Analysis of Activities of 16 Antimicrobial Agents against Gram-Negative Bacteria from Six Teaching Hospitals in China.	2015	25672407

Patents

Sample Use Guides

In Vivo Use Guide

Administration only for intravenous injection or intervenous drop injection. For intravenous injection: Cefminox sodium 1g (valence) can be dissolved in 200ml water for injection, and 5~10% glucose or 0.9% sodium chloride injection. For intervenous drop injection: Cefminox sodium 1g (valence) can be dissolved in 100~500ml 5~10% glucose or 0.9% sodium chloride injection. A drop innjection for 1~2 hours. Recommended dose for adults: 1g (valence) to be administrated twice a day; Adjusted according to the age and symptoms; In septicaemia, and refractory or severe infections, a total daily dosage of 6g (valence) is divided into 3~4 administrations. Recommended dose for children: 20mg (valence)/kg (body weight) to be administrated 3~ 4 times a day.

Route of Administration: Intravenous

In Vitro Use Guide

The MIC50 and MIC90 of cefminox against E. coli were 1.0 mg/L and 4.0 mg/L, respectively.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 16:19:50 GMT 2023` Edited by `admin` on `Sat Dec 16 16:19:50 GMT 2023`
Record UNII	PW08Y13465
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CEFMINOX

Official Name

English

cefminox [INN]

Common Name

English

Cefminox [WHO-DD]

Common Name

English

5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-(((((2S)-2-AMINO-2-CARBOXYETHYL)THIO)ACETYL)AMINO)-7-METHOXY-3-(((1-METHYL-1H-TETRAZOL-5-YL)THIO)METHYL)-8-OXO-, (6R,7S)-

Systematic Name

English

CEFMINOX [MI]

Common Name

English

(6R,7S)-7-(2-(((S)-2-AMINO-2-CARBOXYETHYL)THIO)ACETAMIDO)-7-METHOXY-3-(((1-METHYL-1H-TETRAZOL-5-YL)THIO)METHYL)-8-OXO-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID

Systematic Name

English

5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-((((2-AMINO-2-CARBOXYETHYL)THIO)ACETYL)AMINO)-7-METHOXY-3-(((1-METHYL-1H-TETRAZOL-5-YL)THIO)METHYL)-8-OXO-, (6R-(6.ALPHA.,7.ALPHA.,7(S*)))-

Systematic Name

English

MT-141 FREE ACID

Code

English

5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-((2-(((2S)-2-AMINO-2-CARBOXYETHYL)THIO)ACETYL)AMINO)-7-METHOXY-3-(((1-METHYL-1H-TETRAZOL-5-YL)THIO)METHYL)-8-OXO-, (6R,7S)-

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C357